2023-504199-19-00招募中2 期
An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumours
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Operation
Scientific
T3 Pharmaceuticals AG
研究点 (4)
Loading locations...
相似试验
招募中
3 期
A randomized, open-label, controlled phase III trial comparing the pembrolizumab platinum based chemotherapy combination with pembrolizumab monotherapy in first line treatment of non small-cell lung cancer (NSCLC) patients with PD L1 expression ≥50% on tumor cells : PERSEE TRIAL2024-513697-22-00Centre Hospitalier Regional Et Universitaire De Brest349
已完成
1 期
An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma2023-508524-35-00Biontech US Inc.72
已完成
1 期
A Phase 1, open label, randomized, 2-sequence, 2-period, crossover, single center study to evaluate the pharmacokinetics of follitropin alfa from 2 manufacturing processes, administered as a single subcutaneous 450 IU dose to pituitary-suppressed healthy premenopausal female participants.Infertility2023-507066-91-00Merck Healthcare KGaA14
招募中
1 期
A phase 1, controlled, open-label, single dose, dose-escalation, clinical proof-of-concept study of MRI enhanced with ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in patients with brain amyloid deposits as demonstrated by amyloid PETAlzheimer's disease2024-520078-36-00Alzeca Biosciences Inc.18
招募中
1 期
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours2023-508126-95-00Karolinska University Hospital30